UBS stays neutral on Fisher & Paykel Healthcare and raises price target
Published
The Swiss bank UBS has confirmed its assessment of the shares of New Zealand medical technology company Fisher & Paykel Healthcare. The analysts remain with their "neutral" recommendation. This means that, for now, they advise neither buying nor selling the shares.
At the same time, UBS has raised its price target from 42 to 51 New Zealand dollars. The price target is the price that analysts expect a share to reach in the future. The report is dated the 4th. However, the exact month and year are not stated in the available information.
Fisher & Paykel Healthcare manufactures products for respiratory therapy, including ventilation masks and humidifiers for patients with respiratory diseases. The company is listed on the stock exchanges in New Zealand and Australia. For investors in Germany, the report is of limited interest, as the share is not included in the German stock index (DAX).
UBS did not provide further background on the reasons for the price target increase in the report. The information is limited to the confirmation of the recommendation and the new price forecast.
Sources: MarketScreener Deutschland
More Germany news
- Mercedes-Benz Halts Investment in German Plants and Weighs Closures
- Housing Benefit Cut Dropped: 1.3 Million Households Keep Wohngeld
- Align Technology unveils new innovations for Invisalign treatment
- Large Solar Park in Merbitz Feeds Electricity into the Grid
- Nvidia shares fall sharply: How safe is pension money?
- Telekom baut Rechenzentrum für Industrie und KI aus
- Autonomous Buses to Enter Everyday Life: TUM Leads New DZM Site
- Cigarettes from the EU Abroad: Duty-Free Allowance Not Dropping for Now